VALBIOTIS
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the signature of a research partnership in intestinal microbiota with the MEDIS2 Unit from the Clermont Auvergne University on its active substances TOTUM•070 and TOTUM•448 against dyslipidemia and metabolic liver disease, partly financed by the French National Research Agency. Led by a laboratory shared by the two entities, the MIMETiv project will aim to develop a complete and dynamic human gastrointestinal model integrating the microbiota of the small intestine for the first time. This model will provide exclusive data on the effects and modes of action of Valbiotis' plant-based substances at the intestinal level, in the context of non-drug strategies to combat metabolic and cardiovascular diseases.
Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Board of Directors at Valbiotis states: "In research and development, our public-private partnership strategy is based on collaborations with high scientific added value. The in vitro digestive model project led by the MEDIS Unit is a unique innovation in human digestion research, which we have been following for a long time and to which we are very happy to contribute within this new joint laboratory. As an industrial player, the MIMETiv project represents for us a very promising lever to approach cardiovascular and metabolic diseases from a digestive and intestinal perspective, with a particular focus on the intestinal microbiota. This is an innovative angle, in line with our research and development strategy. At the end of this project, we should obtain exclusive data for our active substances in two of our key indications: dyslipidemia and metabolic liver disease."
Stéphanie BLANQUET-DIOT, Professor and Deputy Director of MEDIS, comments: "This in vitro digestive system is unique in the number of parameters reproduced in relation to in vivo digestion in humans, such as body temperature, pH kinetics in the stomach and small intestine, gastrointestinal transit time, differential gastric emptying between liquids and solid particles, salivary, gastric, biliary and pancreatic secretions, absorption of water and digestive products, progressive anaerobics along the digestive tract and microbiota in small intestine-reproducing compartments."
Dyslipidemia and metabolic liver disease (NAFL, NASH), the respective indications for the active substances TOTUM•070 and TOTUM•448, are highly prevalent diseases, precursors to pathologies that are life-threatening for patients (atherosclerosis, cirrhosis). Their complex pathophysiology includes, among other aspects, alterations in carbohydrate and/or lipid metabolism, digestive abnormalities and disturbances of the intestinal microbiota, all of which the MIMETiv project will be able to approach in humans in an integrated manner. Among the main innovations, MIMETiv should provide access to the microbiota of the small intestine, the major site of digestion and absorption of dietary carbohydrates and lipids in humans. To date, data linking metabolic diseases and gut microbiota have mainly been obtained from stool analysis, which partially reflects the microbiota of the colon (large intestine).
The MIMETiv project: an exclusive tool for R&D on metabolic and cardiovascular diseases
The MIMETiv project, which will benefit from the combined expertise of the MEDIS Unit and Valbiotis, will take place in two stages.
The first will lead to the design of the world's most complete model of the human digestive environment in 2024, based on the long-standing in vitro simulation work of the MEDIS Unit. The work will consist in optimizing the ESIN (Engineered Stomach and Small Intestine) system, developed by MEDIS, by improving its performance and integrating the human microbiota in key compartments of the digestive tract such as the small intestine.
Once validated, this model will constitute a proprietary tool for the evaluation of Valbiotis' plant-based active substances in the human digestive environment. The explorations performed will cover a complete set of R&D objectives for two active substances, TOTUM•070 and TOTUM•448:
- metabolomic analysis, to identify the metabolites of these active substances and to specify their bioavailability in the different gastrointestinal compartments;
- analysis of modes of action, to evaluate their effects on digestion and intestinal absorption of lipids and carbohydrates;
- analysis of the intestinal microbiota, to evaluate their impact on dysbiosis associated with metabolic diseases;
- analysis of hepatic metabolic pathways, thanks to the original coupling of ESINs with liver cells in culture, to assess their possible modulation by Valbiotis' active substances.
The Management Committee of the MIMETiv joint laboratory is composed of 5 members. It is co-led by Stéphanie BLANQUET-DIOT, Deputy Director of MEDIS, in charge of the digestive environment simulation platform, with strong expertise in microbiology and intestinal microbiota, in vitro digestion, digestive physiology and nutrition, and Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Valbiotis Board of Directors. He is responsible for the R&D platform in Riom, with extensive expertise in metabolic diseases and the development of plant-based health products.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022 and completed by an amendment on November 8, 2022. This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1MIMETiv: Microbiote intestinal et maladies métaboliques chez l’Homme (Intestinal microbiota and metabolic diseases in humans): a unique in vitro digestive system to catalyze the development of innovative nutritional strategies.
LabCom Scientific document.
2The MEDIS Unit (Microbiologie Environnement Digestif et Santé: Microbiology Digestive Environment and Health) is a Joint Research Unit between INRAE (Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement: National Research Institute for Agriculture, Food and the Environment) and UCA (Clermont Auvergne University) created in January 2017.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom